PubMed Health⌕ Search

PubMed · 14871787

Root adaptation and nitrogen source acquisition in natural ecosystems.

Abstract

The capacity for nitrate reduction, as measured by nitrate reductase activity (NRA), was generally low for a range of plant communities in Australia (coastal heathland, rainforest, savanna woodland, monsoon forest, mangrove, open Eucalyptus forest, coral cay open forest) and only a loose relationship existed between NRA and leaf nitrogen concentration. This suggests that nitrate ions are not the sole nitrogen source in these communities. Based on (15)N labeling experiments, we found a range of tree species exhibiting a pronounced preference for uptake of ammonium over nitrate. Analysis of soil solutions from several forest and heathland communities indicated that ammonium ions were more prevalent than nitrate ions and that soluble forms of organic nitrogen (amino acids and protein) were present in concentrations similar to those of mineral nitrogen. To determine the extent to which root adaptations and associations might broaden nitrogen source utilization to include organic nitrogen, we assessed the effects of various nitrogen sources on seedling growth in sterile culture. Non-mycorrhizal seedlings of Eucalyptus grandis W. Hill ex Maiden and Eucalyptus maculata Hook. grew well on mineral sources of nitrogen, but did not grow on organic sources of nitrogen other than glutamine. Mycorrhizal seedlings grew well on a range of organic nitrogen sources. When offered a mixture of inorganic and organic nitrogen sources at low concentrations, mycorrhizal seedlings derived a significant proportion of their nitrogen budget from organic sources. We also demonstrated that a species of the obligately non-mycorrhizal genus Hakea, a heathland proteaceous shrub possessing cluster roots, had the ability to incorporate (15)N-labeled organic sources (e.g., glycine). We conclude that mycorrhizal associations and root adaptations confer the ability to substantially broaden the nitrogen source base on some plant species.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Matthew H. Turnbull, Susanne Schmidt, Peter D. Erskine, Suanne Richards, George R. Stewart. Root adaptation and nitrogen source acquisition in natural ecosystems.. https://doi.org/10.1093/treephys%2F16.11-12.941

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗